Teva announced the launch of Voriconazole tablets, the generic version of Pfizer‘s Vfend tablets.
Vfend is an azole anti-fungal indicated for fungal infections, particularly invasive aspergillosis, nonneutropenic candidemia, candida infections in abdomen, kidney, bladder, wounds, or skin (disseminated), esophageal candidiasis, and serious infections caused by Scedosporium apiospermum and Fusarium species in patients refractory to, or intolerant of, other agents. Voriconazole inhibits an essential step in ergosterol synthesis, therefore compromising the stability of the fungal cell wall.
Voriconazole tablets are available from Teva in 50mg and 200mg dosage strengths in 30-count bottles.
For more information call (888) TEVA-USA or visit www.tevausa.com.